HMGB1 and septic shock: High pharmacological doses of riboflavin effectively inhibit the HMGB1 release, an important factor in the pathogenesis of endotoxemia [16], and offer a promising therapeutic strategy in sepsis and septic shock as a result of attenuated inflammation, consequently leading to an increase in survival rates among septic animals [32,33,34].